The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.
Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, received CDSCO approval this week.
Novo Nordisk scientists have synthesised an insulin molecule that specifically targets glucose in blood, instead of other sugars like fructose, to aid treatment of all types of diabetes.
Doctors Without Borders says new class of drugs & insulin devices could be leading to ‘exorbitant corporate profiteering’. Study published in Journal of the American Medical Association.
Icodec has been touted as a therapy that could eliminate the need for daily or mealtime insulin injections for people with severe diabetes. It has not been approved by any country so far.
Danish pharmaceutical giant Novo Nordisk has said it is set to apply for regulatory approval of its once-a-week insulin drug, Icodec. Results of Phase-3 clinical trial shown 'promising results'.
UK patients may soon be covered for the device, which measures blood glucose, computes amount of insulin needed and then pumps that exact amount into bloodstream.
SEBI probe concluded that purported loans and fund transfers were paid back in full and did not amount to deceptive market practices or unreported related party transactions.
Many really smart people now share the position that playing cricket with Pakistan is politically, strategically and morally wrong. It is just a poor appreciation of competitive sport.
COMMENTS